Acurx Pharmaceuticals (ACXP) Competitors $0.31 -0.02 (-5.83%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.30 0.00 (-0.65%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. EGRX, PEPG, JSPR, RNXT, LTRN, NBRV, ACRV, OVID, CVM, and ELYMShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Eagle Pharmaceuticals (EGRX), PepGen (PEPG), Jasper Therapeutics (JSPR), RenovoRx (RNXT), Lantern Pharma (LTRN), Nabriva Therapeutics (NBRV), Acrivon Therapeutics (ACRV), Ovid Therapeutics (OVID), CEL-SCI (CVM), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Its Competitors Eagle Pharmaceuticals PepGen Jasper Therapeutics RenovoRx Lantern Pharma Nabriva Therapeutics Acrivon Therapeutics Ovid Therapeutics CEL-SCI Eliem Therapeutics Acurx Pharmaceuticals (NASDAQ:ACXP) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends. Do analysts rate ACXP or EGRX? Acurx Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 2,505.86%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Acurx Pharmaceuticals is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation and earnings, ACXP or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than Acurx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.10M-$0.70-0.44Eagle Pharmaceuticals$257.55M0.16$35.64MN/AN/A Which has more risk and volatility, ACXP or EGRX? Acurx Pharmaceuticals has a beta of -1.26, indicating that its share price is 226% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Do insiders and institutionals believe in ACXP or EGRX? 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 26.0% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to ACXP or EGRX? In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for Eagle Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.34 beat Eagle Pharmaceuticals' score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acurx Pharmaceuticals Neutral Eagle Pharmaceuticals Neutral Is ACXP or EGRX more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -526.78% -223.78% Eagle Pharmaceuticals N/A N/A N/A SummaryEagle Pharmaceuticals beats Acurx Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.03M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-0.4417.6228.6723.80Price / SalesN/A179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book10.238.508.275.55Net Income-$14.10M-$55.06M$3.24B$259.03M7 Day Performance-24.37%-3.98%-3.69%-4.59%1 Month Performance-36.92%9.59%4.33%4.46%1 Year Performance-85.45%6.72%25.95%18.03% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.592 of 5 stars$0.31-5.8%$8.00+2,505.9%-85.7%$10.03MN/A-0.443News CoverageEGRXEagle Pharmaceuticals1.9805 of 5 stars$3.69flatN/A-33.3%$47.92M$257.55M0.00100Gap DownPEPGPepGen2.6609 of 5 stars$1.43-1.4%$7.67+436.1%-86.9%$47.44MN/A-0.4630Gap DownJSPRJasper Therapeutics2.7047 of 5 stars$3.10-1.6%$29.75+859.7%-83.4%$47.32MN/A-0.5920RNXTRenovoRx2.3268 of 5 stars$1.25-1.6%$7.25+480.0%-1.6%$46.45M$40K-3.136Analyst DowngradeLTRNLantern Pharma2.296 of 5 stars$4.01-5.4%$25.00+523.4%+17.5%$45.67MN/A-2.1820News CoverageUpcoming EarningsShort Interest ↑Gap DownNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070ACRVAcrivon Therapeutics2.776 of 5 stars$1.43flat$17.71+1,138.8%-83.9%$44.84MN/A-0.6458OVIDOvid Therapeutics4.651 of 5 stars$0.53-14.7%$3.13+492.4%-49.5%$43.98M$570K-1.5160Positive NewsGap DownCVMCEL-SCI1.2111 of 5 stars$8.66+5.6%N/A-72.6%$43.64MN/A-18.0443Positive NewsShort Interest ↑High Trading VolumeELYMEliem TherapeuticsN/A$1.45-2.0%N/A-80.9%$43.14MN/A-2.749 Related Companies and Tools Related Companies Eagle Pharmaceuticals Alternatives PepGen Alternatives Jasper Therapeutics Alternatives RenovoRx Alternatives Lantern Pharma Alternatives Nabriva Therapeutics Alternatives Acrivon Therapeutics Alternatives Ovid Therapeutics Alternatives CEL-SCI Alternatives Eliem Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
